Biomarker-driven and molecular targeted therapies for colorectal cancers

Marta Schirripa, Stacey A. Cohen, Francesca Battaglin, Heinz Josef Lenz

Research output: Contribution to journalArticlepeer-review


Improved clinical selection and identification of new molecules and innovative strategies have widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and probably will be soon adopted into daily clinical practice. In the present review, the role RAS, BRAF mutations, Her2 amplification, microsatellite instability, and CpG island methylator phenotype are discussed according to their possible roles as prognostic, predictive markers, as well as possible biomarker-driven treatment options.

Original languageEnglish
Number of pages9
JournalSeminars in Oncology
Early online dateJul 4 2017
Publication statusE-pub ahead of print - Jul 4 2017


  • BRAF
  • CpG island methylator phenotype
  • HER2
  • Microsatellite instability
  • RAS

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Biomarker-driven and molecular targeted therapies for colorectal cancers'. Together they form a unique fingerprint.

Cite this